News for Karyopharm Therapeutics Inc. (KPTI)

PR NewswireNEWTON, Mass., Feb. 24, 2025 NEWTON, Mass., Feb. 24, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharma

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q4 2024 Earnings Call February 19, 2025 8:00 AM ETCompany ParticipantsBrendan Strong - SVP, IRRichard Paulson -...

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 7.69% and 0.83%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

The following slide deck was published by Karyopharm Therapeutics Inc.

XPOVIO® is the first XPO1 inhibitor approved in Taiwan for the treatment of adult patients with relapsed/refractory multiple myeloma (R/R MM). After the mainland of China, South Korea, Australia and Singapore, Taiwan market is the fifth APAC market in which XPOVIO® has been approved for public health insurance coverage. XPOVIO® is expected to extend public health insurance coverage across APAC markets. SHANGHAI and HONG KONG, Feb. 13, 2025 /PRNewswire/ -- Antengene Corporation Limited ('Antengene', SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced that XPOVIO® (selinexor) in combination with bortezomib and dexamethasone (XVd) for the treatment of adult patients with relapsed/refractory multiple myeloma (R/R MM) who have received at least two prior therapies, has been approved for reimbursement in Taiwan. Starting from March 1, 2025, XPOVIO® will be officially included in the NHI drug reimbursement scheme.

PR NewswireNEWTON, Mass., Feb. 12, 2025 -- Conference Call Scheduled for Wednesday, February 19, 2025, at 8:00 a.m. ET --NEWTON, Mass., Feb. 12, 2025 /PRNe

PR NewswireNEWTON, Mass., Jan. 2, 2025 NEWTON, Mass., Jan. 2, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmace

PR NewswireNEWTON, Mass., Jan. 2, 2025 NEWTON, Mass., Jan. 2, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmace

Karyopharm Therapeutics appoints Lori Macomber as CFO. Macomber brings experience from Legend Biotech.

KPTI stock touches 52-week low at $0.65 amid market challenges

Shares of Edgewise Therapeutics, Inc. EWTX rose sharply in today's pre-market trading after the company reported topline results from Phase 2 CANYON trial of Se...

PR NewswireNEWTON, Mass., Dec. 9, 2024 NEWTON, Mass., Dec. 9, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmace

Karyopharm CEO Richard Paulson sells $2,932 in stock

PR NewswireNEWTON, Mass., Dec. 3, 2024 NEWTON, Mass., Dec. 3, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmace

PR NewswireNEWTON, Mass., Dec. 2, 2024 NEWTON, Mass., Dec. 2, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmace

SHANGHAI and HONG KONG, Nov. 28, 2024 /PRNewswire/ -- Antengene Corporation Limited ('Antengene', SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic malignancies and solid tumors, today announced that the new indication of XPOVIO® (selinexor) in adult patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) who have received at least two lines of systematic therapy, has been included into the 2024 China National Reimbursement Drug List (NRDL) which will officially take effect on January 1, 2025.

Antengene to Present Results from Two Late-Stage Studies of Selinexor Signaling Potential Clinical Breakthrough at ASH 2024

~ Pierre S. Sayad, PhD, M.S., Appointed Chief Medical Officer ~

This approval for XPOVIO® for the treatment of patients with multiple myeloma (MM) marks the third approved indication of the drug in South Korea. To date, XPOVIO® has already been included in national health insurance or reimbursement schemes in South Korea, the mainland of China, Australia and Singapore, and is expected to achieve national reimbursement coverage in more APAC markets. XPOVIO® has been approved for multiple indications in nine markets across the APAC region. Antengene has submitted a new drug application (NDA) for XPOVIO® in Indonesia with approval expected in the second half of 2024. SHANGHAI and HONG KONG, Oct. 18, 2024 /PRNewswire/ -- Antengene Corporation Limited ('Antengene', SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic malignancies and solid tumors, today announced that the South Korean Ministry of Food and Drug Safety (MFDS) has approved a supplemental New Drug Application (sNDA) for XPOVIO® (selinexor) in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy.